Measles is a highly contagious disease that can lead to severe complications, and millions of children are at risk. A new study shows innovative technology can reduce key barriers in administering a life-saving vaccine.
Getting children the required two doses of the vaccine can be challenging for countries struggling to prevent outbreaks. The vaccine requires continuous refrigeration—no small feat in rural communities without consistent electricity. It also requires an injection only trained health workers can administer. In the first clinical trial of a new injection-free vaccine delivery technology, results point to a promising alternative to getting children the protection they deserve. The study—supported by the Bill & Melinda Gates Foundation and the CDC, core members of the Measles & Rubella Partnership—evaluated the safety and effectiveness of a measles-rubella vaccine patch in 120 toddlers, 120 infants, and 45 adults in The Gambia.
Results show the painless patch is safe and generates similar immune responses to those delivered via syringe, eliminating the need for cold storage and highly trained health workers. It also did not produce any allergic reactions or serious effects. This injection-free technology has the potential to raise vaccination rates and stop the spread of measles and rubella. By harnessing this groundbreaking innovation and others like it, we can shield children and their families from this deadly disease.
Read more about the study on NPR’s Goats and Soda.